Whistleblower due $250M in Biogen drug kickback settlement

Biogen has agreed to pay $900 million to resolve allegations stemming from a whistleblower lawsuit alleging the drugmaker paid kickbacks to physicians to induce them to prescribe the company's multiple sclerosis drugs.